Bioavailability and in vivo efficacy of a praziquantel-polyvinylpyrrolidone solid dispersion in Schistosoma mansoni-infected mice

被引:15
作者
El-Lakkany, Naglaa [1 ]
Seif el-Din, Sayed Hassan [1 ]
Heikal, Lamia [2 ]
机构
[1] Theodor Bilharz Res Inst, Dept Pharmacol, Giza 12411, Egypt
[2] Univ Alexandria, Fac Pharm, Dept Pharmaceut, Alexandria, Egypt
关键词
Praziquantel; Solid dispersion; Polyvinylpyrrolidone; S; mansoni; Bioavailability; In vivo efficacy; DRUG-METABOLIZING-ENZYMES; DISSOLUTION PROPERTIES; RELEASE; VITRO; MECHANISMS; RESISTANT; PVP; PHARMACOKINETICS; ALBENDAZOLE; SENSITIVITY;
D O I
10.1007/s13318-012-0089-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
One of the problems of praziquantel (PZQ) is its very low aqueous solubility. Moreover, its dissolution rate is considered the limiting factor for its bioavailability. This work correlates the physical properties and the dissolution behavior of PZQ-polyvinylpyrrolidone (PVP) solid dispersion (SD) at the ratios of 1:1 and 3:7 with its oral bioavailability and its in vivo efficacy against Schistosoma mansoni (S. mansoni). The PZQ and PZQ-PVP SD were characterized by infrared spectroscopy, differential scanning calorimetry, scanning electron microscopy (SEM) and solubility test. Results showed a decrease in crystallinity, possible interaction between PZQ and PVP, greater increase in dissolution rate and appreciable reduction in particle size. S. mansoni-infected mice treated orally with either pure PZQ or PZQ-PVP at a single dose of 500 mg/kg showed a higher increase in AUC((0-8h)), C (max), K (a) and t (1/2e) with a significant decrease in k (el) versus the corresponding uninfected mice. Moreover, uninfected and infected mice treated with PZQ-PVP SD showed 2.3-, 1.6- and 1.3-, 1.25-fold increase, respectively, in AUC((0-8h)) and C (max), with a decrease in k (el) and increase in t (1/2e) by twofold versus the corresponding pure PZQ-treated groups. Percentage worm reduction at all administered doses (62.5, 125, 250, 500 and 1,000 mg/kg) was significantly higher (1- to 1.5-fold) in mice treated with PZQ-PVP SD (ED50 = 40.92) versus those treated with pure PZQ (ED50 = 99.29). In addition, a significant reduction in total tissue egg load concomitant with a significant decrease in total immature and mature eggs and an increase in dead eggs in PZQ-PVP SD-treated groups versus their corresponding pure PZQ-treated groups was recorded. Solid dispersion of PZQ with PVP could lead to a further improvement in the effectiveness of PZQ therapy especially with the appearance of some PZQ-tolerant S. mansoni isolates.
引用
收藏
页码:289 / 299
页数:11
相关论文
共 55 条
[1]   LIPOSOMAL DELIVERY SYSTEM FOR THE TARGETING AND CONTROLLED RELEASE OF PRAZIQUANTEL [J].
AKBARIEH, M ;
BESNER, JG ;
GALAL, A ;
TAWASHI, R .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1992, 18 (03) :303-317
[2]   EFFECT OF PRAZIQUANTEL ON CLINICAL-CHEMICAL PARAMETERS IN HEALTHY AND SCHISTOSOME-INFECTED MICE [J].
ANDREWS, P ;
DYCKA, J ;
FRANK, G .
ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY, 1980, 74 (02) :167-177
[3]  
Andrews P., 1976, Veterinary Medical Review, P154
[4]   POSSIBLE MECHANISMS OF ALTERATION IN THE CAPACITIES OF CARCINOGEN METABOLIZING ENZYMES DURING SCHISTOSOMIASIS AND THEIR ROLE IN BLADDER-CANCER INDUCTION [J].
BADAWI, AF ;
MOSTAFA, MH .
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 1993, 21 (06) :281-305
[5]   Comparative efficacy and bioavailability of different praziquantel brands [J].
Botros, Sanaa ;
El-Lakkany, Naglaa ;
el-Din, Sayed H. Seif ;
Sabra, Abdel-Nasser ;
Ibrahim, Magda .
EXPERIMENTAL PARASITOLOGY, 2011, 127 (02) :515-521
[6]   Drug-metabolizing enzymes and praziquantel bioavailability in mice harboring Schistosoma mansoni isolates of different drug susceptibilities [J].
Botros, Sanaa S. ;
el-Din, Sayed H. Seif ;
El-Lakkany, Naglaa M. ;
Sabra, Abdel Nasser A. ;
Ebeid, Fatma A. .
JOURNAL OF PARASITOLOGY, 2006, 92 (06) :1344-1349
[7]  
Brant P C, 1979, Rev Inst Med Trop Sao Paulo, V21, P254
[8]   Chemotherapy of schistosomiasis: present and future [J].
Caffrey, Conor R. .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2007, 11 (04) :433-439
[9]  
CHEEVER A W, 1968, Bulletin of the World Health Organization, V39, P328
[10]   PHARMACEUTICAL APPLICATIONS OF SOLID DISPERSION SYSTEMS [J].
CHIOU, WL ;
RIEGELMAN, S .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1971, 60 (09) :1281-+